<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507468</url>
  </required_header>
  <id_info>
    <org_study_id>ABM-MI-10</org_study_id>
    <nct_id>NCT00507468</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone</brief_title>
  <acronym>TABMMI</acronym>
  <official_title>Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this open-labeled, uncontrolled pilot study was to investigate the safety and&#xD;
      feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the&#xD;
      myocardium using the helical needle transendocardial (TE) delivery system in stable coronary&#xD;
      patients with ventricular dysfunction due to chronic myocardial infarction (MI).&#xD;
&#xD;
      A secondary goal was to assess the possibility that such cell injections could improve&#xD;
      ejection fraction (EF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Ventricular Dysfunction</condition>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transendocaridal Transplantation of Autologous Bone Marrow</intervention_name>
    <description>Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Must have documentation of prior myocardial infarction with left ventricular ejection&#xD;
             fraction of less than 40 percent at baseline&#xD;
&#xD;
          -  Must be a candidate for percutaneous heart catheterization&#xD;
&#xD;
          -  Must have identifiable area of transmural scar within the left ventricle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be a candidate for concurrent ventricular surgical restoration, AICD placement or&#xD;
             valvular surgery&#xD;
&#xD;
          -  Clinical evidence of infection&#xD;
&#xD;
          -  Other complicating cardiovascular abnormalities&#xD;
&#xD;
          -  Clinically significant electrocardiographic abnormalities&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Recent history or drug or alcohol abuse&#xD;
&#xD;
          -  Pregnancy, planned or current&#xD;
&#xD;
          -  Artificial aortic valve&#xD;
&#xD;
          -  Ejection fraction less than 30 percent at baseline&#xD;
&#xD;
          -  Myocardial infarction in the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis de la Fuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Argentine Institute of Diagnosis and Treatment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Clinic</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Argentine Institute of Diagnosis and Treatment</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1122</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>July 22, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>November 2, 2009</last_update_submitted>
  <last_update_submitted_qc>November 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter Altman</name_title>
    <organization>BioCardia, Inc</organization>
  </responsible_party>
  <keyword>bone marrow</keyword>
  <keyword>autologous</keyword>
  <keyword>ejection fraction</keyword>
  <keyword>left ventricle</keyword>
  <keyword>heart attack</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>left ventricular dysfunction post myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

